Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 August 2005

M2000: A Revolution in Pharmacology

Abbas Mirshafiey, Salvatore Cuzzocrea, Bernd Rehm, Hidenori Matsuo

Med Sci Monit 2005; 11(8): PI53-63 :: ID: 202335

Abstract

Background: The tolerability and the anti-inflammatory and immunosuppressiveproperties of a novel designed non-steroidal anti-inflammatory drug, M2000 (beta-D-mannuronic acid),were investigated in various experimental models. Material/Methods: The anti-inflammatory and immunosuppressiveproperties of M2000 were tested in experimental models of rheumatoid arthritis (AIA) and multiple sclerosis(EAE). Its therapeutic potency on kidney diseases was studied using experimental models of nephrosisand immune complex glomerulonephritis (ICG). Biocompatibility and pharmacotoxicology assessment of M2000was carried out using a fibrosarcoma cell line, zymography, and serum and urine determinants. Results:Data showed that oral and/or i.p. administration of M2000 significantly reduces paw edema and histopathologicalparameters in arthritic rats. The immunosuppressive property of M2000 could significantly diminish clinicalsigns and histological erosions in the EAE model. Lymph node cell proliferation assay in EAE confirmedthe immunosuppressive efficacy of the tested drug. Our findings in ICG and experimental nephrosis showedthat M2000 enables a significant decrease in proteinuria, BUN, serum creatinine and cholesterol, as wellas glomerular lesion in M2000-treated rats. Moreover, this drug inhibited MMP-2 activity. The pharmacotoxicologystudy showed that M2000 is the safest anti-inflammatory and immunosuppressive drug in comparison withdexamethasone and conventional NSAIDs tested. Additionally, M2000 had no ulcerogenic effect on the ratstomach. Conclusions: M2000 is the first novel designed NSAID with the lowest molecular weight, no gastro-nephrotoxicity,and therapeutic effects in glomerulonephritis and nephrosis and could be strongly recommended on an extensivescale as the safest drug for decreasing anti-inflammatory reactions.

Keywords: Hydrocarbons - administration & dosage, Hydrocarbons - therapeutic use, Multiple Sclerosis - chemically induced, Anti-Inflammatory Agents, Non-Steroidal - therapeutic use, Antibodies - immunology, Arthritis, Experimental - pathology, Arthritis, Rheumatoid - pathology, Cattle, Cell Proliferation - drug effects, Glomerulonephritis - urine, Hindlimb - pathology, Hydrocarbons - therapeutic use, Immunosuppression, Interleukin-6 - metabolism, Lipids - blood, Matrix Metalloproteinase 2 - metabolism, Multiple Sclerosis - pathology, Neurons - pathology, Rats, Inbred Lew, Serum Albumin, Bovine - immunology

Add Comment 0 Comments

Editorial

01 February 2025 : Editorial  

Editorial: Current Approaches to Screening for Lung Cancer in Smokers and Non-Smokers

Dinah V. Parums

DOI: 10.12659/MSM.948255

Med Sci Monit 2025; 31:e948255

0:00

In Press

Clinical Research  

Procedure Dynamics in Transfemoral vs Transradial Cerebral Angiography: A Retrospective Study

Med Sci Monit In Press; DOI: 10.12659/MSM.947603  

Clinical Research  

Predicting Cerebral Small Vessel Disease Burden Based on Thromboelastography in Patients with Acute Ischemi...

Med Sci Monit In Press; DOI: 10.12659/MSM.946303  

Clinical Research  

Long-Term Outcomes of Implanon in Managing Adenomyosis: A 3-Year Prospective Study

Med Sci Monit In Press; DOI: 10.12659/MSM.945972  

Laboratory Research  

Linear Dimensional Accuracy in Maxillomandibular Records: A Comparative Study of Scannable and Transparent ...

Med Sci Monit In Press; DOI: 10.12659/MSM.947265  

Most Viewed Current Articles

17 Jan 2024 : Review article   6,969,459

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

16 May 2023 : Clinical Research   701,879

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

01 Mar 2024 : Editorial   25,628

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...

DOI :10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

28 Jan 2024 : Review article   20,173

A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and Future

DOI :10.12659/MSM.943912

Med Sci Monit 2024; 30:e943912

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750